Short answer
PTC THERAPEUTICS, INC. (PTCT) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $211M (up 7.2% year over year) with net income of $16M.
Q3 2025 key financials · XBRL
- Revenue
- $211M
- +7.2% YoY · +18.0% QoQ
- Net income
- $16M
- +114.9% YoY · +124.5% QoQ
- Operating margin
- 1.4%
- EPS (diluted)
- $0.16
- +111.5% YoY · +121.3% QoQ
Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) Q3 2025 10-Q on SEC EDGAR. USD.
PTC THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New director/officer trading arrangements under Rule 10b5-1 adopted Sept 2025 for sales up to 259,346 shares, latest expiring March 2027
- Updated insider trading compliance risk reflecting expanded use of Rule 10b5-1 plans to manage equity sales and tax obligations
- Legal and compliance risk from adherence to SEC Rule 10b5-1 and insider trading laws with multiple overlapping trading plans disclosed
- Operational risk from potential variability in stock sales by insiders impacting market perception and share price dynamics in near term
- Financial risk of equity concentration with large insider sales authorized, up to 259,346 shares within 1.5 years, potentially affecting liquidity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PTC THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.